The FDA has approved daprodustat (Jesduvroq, GSK) for the once daily treatment of anemia caused by chronic kidney disease (CKD) in adults administered dialysis for at least 4 months. 1 The oral ...

The FDA has approved daprodustat, the first oral treatment for anemia for adults receiving dialysis for at least 4 months. Daprodustat is the first hypoxia-inducible factor prolyl hydroxylase ...

The US Food and Drug Administration (FDA) has approved daprodustat (Jesduvroq), the first oral treatment for anemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for ...

The FDA is due to make an approval decision on GSK's drug by Feb. 1, 2023. Outside the U.S., daprodustat is also in the running for marketing authorization in Europe.

Jesduvroq (daprodustat) approved by US FDA for anemia of chronic kidney disease in adults on dialysis. News release. GSK plc. February 1, 2023. Accessed February 2, 2023.

Roxadustat failed FDA approval due to issues with seizures, infections and thromboembolic disease (including VAT in patients on dialysis) that were not seen with daprodustat. Vadadustat failed FDA ...

The Food and Drug Administration has approved Jesduvroq tablets (daprodustat), the first oral treatment for renal disease-related anemia in adults who have been on dialysis for four months or more ...

The FDA has approved Jesduvroq tablets for treatment of anemia in patients with chronic kidney disease who are on dialysis, according to a press release.The agency qualified the approval by ...

GSK PLCGSK announced that the FDA approved its daprodustat drug, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), treatment of anemia due to chronic kidney disease (CKD) in ...

GSK plc GSK announced that the FDA has informed that it will conduct an advisory committee meeting to review the new drug application (NDA) seeking approval of daprodustat, an oral hypoxia ...

(RTTNews) - The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been ...

· Jesduvroq is the only oral HIF-PHI approved in the US, offering adults on dialysis with anaemia of chronic kidney disease a new oral treatment option Tony Wood, President and Chief Scientific ...